Friday, 16 Nov 2018

You are here

IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.

Efficacy of a IL-17A neutralizing antibody secukinumab, and most importantly its role in inhibition of structutal damage, was assessed in FUTURE 5, the largest randomized controlled trial of a biologic conducted to date in PsA.

996 active TNF-experienced (30% of the patients) and TNF-naive PsA patients were randomized 2:2:2:3 to receive sc secukinumab 300 mg with loading dosage (LD),150 mg with LD, 150 mg without LD, or placebo (PBO).

Primary end point of ACR 20 at week 16 was met with significantly better scores in all secukinumab groups 62.6% (300mg), 55.5 (150mg), 59.5% (150 w/out LD) vs 27.4% PBO.

Secondary end point was radiographic progression in peripheral joints (hand/wrist/foot) measured but mTSS at weeks 16 and 24. Significantly greater proportion of pts had no radiographic progression (change from BL in mTSS≤0.5) with secukinumab vs. PBO: 88% (300 mg), 79% (150 mg), 83% (150 mg w/out LD), and 73% (PBO).

Patients who received 150mg w/out LD took longer to achieve response in comparison to 300 mg and 150 mg w/LD, and resolution of dactyitis and enthesitis was not statistically significant in this group.

Adverse event (AE) rates at Wk 16 were 51.8% (300 mg), 52.7% (150 mg), 52.7% (150 mg without LD) and 58.7% (PBO); non-fatal serious AE rates were 2.3%, 3.2%, 1.4%, and 3.0%, respectively. No deaths were reported.

 

In summary, sq secukinumab 300 mg with LD and 150 mg with and without LD inhibited radiographic structural progression and provided rapid and clinically significant improvements in the signs, symptoms and physical function of pts with PsA. The safety profile was consistent with that previously reported with no new safety signals identified.

Add new comment

More Like This

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Doubling Down on IL-17 In Psoriatic Arthritis

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

Updates on Psoriatic Arthritis at ACR 2018

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.

Axial Spondylitis Abstracts Roundup

There have been a number of interesting posters and presentations covering the field of axial spondyloarthropathy. I’ve picked out a few points that I found particularly relevant.

Classification Criteria

NK cells and a Potential Role in the Development of PsA vs PsC (Cutaneous Psoriasis)

Human NK cells express multiple receptors that interact with HLA class I molecules which, in turn, suppy peptides that bind HLA-E to form CD94/NKG2A NK receptor ligands. These peptides correspond to -22 to -14 residues in the leader sequences of HLA-A, HLA-B and HLA-C binding to the HLA-E site. Methionine – 21 delivers functional peptides in stark contrast to threonine – 21 which does not.